Streetbeat News

Equity Actions

TBRG

TruBridge, Inc. (NASDAQ:TBRG), a healthcare solutions company, announced the adoption of a limited duration stockholder rights plan to protect stockholders' interests and ensure all stockholders can realize the long-term value of their investment. This Rights Plan is designed to prevent any entity from gaining control without negotiating with the Board and paying a control premium.

Portfolio Pulse from Benzinga Newsdesk

March 26, 2024 | 12:07 pm

SNX

TD SYNNEX has announced a new $2 billion share repurchase authorization, signaling confidence in the company's financial health and a commitment to returning value to shareholders.

Portfolio Pulse from Benzinga Newsdesk

March 26, 2024 | 12:07 pm

MAIA

MAIA Biotechnology, Inc. (NYSE:MAIA) announced a private placement of 578,643 shares at $2.295/share, raising approximately $1.33M. The offering includes warrants exercisable at $2.55/share, starting six months post-issuance with a five-year term. The funds are designated for R&D, specifically for a part of the THIO-101 trial in NSCLC.

Portfolio Pulse from Benzinga Newsdesk

March 26, 2024 | 12:06 pm

WATT

Energous Corporation (NASDAQ:WATT) announced a leadership change with Cesar Johnston stepping down as President & CEO, effective immediately. The Board is searching for a successor and has established an Office of the Chair for interim leadership. The company remains focused on its IoT-centric strategy and the adoption of its WattUp wireless power technology. A financial results conference call is scheduled for March 28.

Portfolio Pulse from Benzinga Newsdesk

March 26, 2024 | 12:03 pm

APCX

AppTech Payments Corp. has announced the pricing of a 2 million share offering at $1 per share, aiming to raise capital for its operations.

Portfolio Pulse from Benzinga Newsdesk

March 26, 2024 | 12:03 pm

GDS

GDS Holdings shares dropped following the announcement of its Q4 results, an equity raise, and the appointment of a new CEO for its international business.

Portfolio Pulse from Benzinga Newsdesk

March 26, 2024 | 12:02 pm

HGV

Analyst ratings for Hilton Grand Vacations (NYSE:HGV) show a mix of bullish and bearish perspectives with an average 12-month price target of $57.83, indicating a 14.13% increase from the previous target. The company's financial performance includes a revenue growth rate of 2.72% and a net margin of 6.67%, but it faces challenges with lower ROE and ROA compared to industry averages. Analysts' actions and price target adjustments reflect their evolving expectations for HGV.

Portfolio Pulse from Benzinga Insights

March 26, 2024 | 12:01 pm

EPD

Enterprise Prods Partners (NYSE:EPD) has received diverse analyst ratings over the last three months, with 5 analysts offering perspectives ranging from bullish to bearish. The average 12-month price target is $33.4, indicating a 5.2% increase from the previous target. Analysts from Barclays, Truist Securities, RBC Capital, Wells Fargo, and Stifel have adjusted their ratings and price targets, reflecting dynamic market conditions and company performance. Enterprise Products Partners, a major midstream company, has shown notable revenue growth and effective asset utilization but faces challenges in profitability and equity capital utilization.

Portfolio Pulse from Benzinga Insights

March 26, 2024 | 12:01 pm

LPRO

Open Lending (NASDAQ:LPRO) has received mixed analyst ratings over the past three months, with a shift towards a more neutral stance in the last 30 days. The average 12-month price target for LPRO has been raised to $7.7, indicating a 28.33% increase from the previous target. Financial analysis reveals challenges for Open Lending, including a significant revenue decline of -44.3%, below-average net margin and ROE, and a high debt-to-equity ratio, suggesting potential financial strain.

Portfolio Pulse from Benzinga Insights

March 26, 2024 | 12:00 pm

ADMA

ADMA Biologics (NASDAQ:ADMA) has received mixed analyst ratings over the last three months, with a shift towards more bullish perspectives recently. The average 12-month price target for ADMA has increased to $7.75, up 15.67% from the previous target of $6.70. Analysts from firms like HC Wainwright & Co., Mizuho, and Cantor Fitzgerald have raised their price targets, reflecting a positive outlook on the company's performance. ADMA Biologics, a commercial biopharmaceutical company, has shown significant revenue growth of 47.86% as of December 31, 2023, and has outperformed in net margin and ROE compared to industry averages. However, the company faces challenges in debt management with a higher than average debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

March 26, 2024 | 12:00 pm